Testing effectiveness (Phase 2)Looking for participantsNCT06571734
What this trial is testing
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
Who this might be right for
Metastatic LeiomyosarcomaUnresectable LeiomyosarcomaBone Sarcoma+7 more
Northwestern University 73